Alvotech
Alvotech appoints Lisa Graver as CEO
February 3, 2026Alvotech, CEO
Alvotech has announced the appointment of Lisa Graver as CEO, following the retirement of Róbert Wessman. Wessman served as Chairman …
Alvotech biosimilar receives EC marketing approval
November 26, 2025Research and Development Alvotech, Immunology, Inflammatory disease, Rheumatology
The European Commission (EC) has granted marketing authorisation for Gobivaz, Alvotech’s first-in-market biosimilar of Simponi (golimumab), which is used for …
Alvotech and Advanz Pharma announce commercialisation agreement for Eylea biosimilar
June 18, 2024Sales and Marketing Advanz Pharma, Alvotech, Opthalmology, biosimilar
Alvotech and Advanz Pharma have announced an exclusive partnership agreement surrounding the supply and commercialisation of AVT06, Alvotech’s proposed biosimilar …
Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada
November 15, 2023Medical Communications Alvotech, Health Canada, JAMP Pharma, Pharmacy, biosimilar
Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation for AVT04, a biosimilar to …
Alvotech recruit new CEO from within
August 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alvotech, biotech, drugs, pharma, pharmaceutical
Alvotech, a biopharmaceutical company focusing on the development and manufacture of based in Reykjavik, Iceland, has replaced outgoing CEO, Eef …
Pharma manufacturing news in brief
March 18, 2014Manufacturing and Production Aesica, Alvotech, Codexis/Intrexon, Pluristem, Updates from Bayer
Bayer says it plans to invest more than €500 million to establish additional manufacturing capacity for its haemophilia drugs at …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
